Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Uterine Cervical Neoplasms 1Neurotoxicity Syndromes 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gliosarcoma 1Glioma 1Glioblastoma 1Cytokine Release Syndrome 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Carboplatin 171Paclitaxel 129Radiotherapy 119Cisplatin 109Docetaxel 93Gemcitabine 81Erlotinib Hydrochloride 80Pemetrexed 78Bevacizumab 56Etoposide 41pembrolizumab 36Gefitinib 32Vinorelbine 31Topotecan 30Surveys and Questionnaires 29Irinotecan 28Radiosurgery 21Nivolumab 20Drug Therapy 20Magnetic Resonance Spectroscopy 18Cetuximab 18durvalumab 17Early Intervention, Educational 17Blood Specimen Collection 17Surgical Procedures, Operative 16Cyclophosphamide 16Celecoxib 15Ipilimumab 14Immunohistochemistry 14Filgrastim 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lung Neoplasms × Contrast Media × Clear all
NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled 17 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡